Your browser is no longer supported. Please, upgrade your browser.
Settings
CYCCP Cyclacel Pharmaceuticals, Inc. daily Stock Chart
CYCCP [NASD]
Cyclacel Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.64 Insider Own- Shs Outstand12.50M Perf Week3.01%
Market Cap62.49M Forward P/E- EPS next Y- Insider Trans- Shs Float11.70M Perf Month-5.84%
Income- PEG- EPS next Q- Inst Own0.69% Short Float0.00% Perf Quarter-9.65%
Sales0.15M P/S416.58 EPS this Y- Inst Trans- Short Ratio0.11 Perf Half Y-27.16%
Book/sh1.29 P/B3.89 EPS next Y- ROA- Target Price- Perf Year-21.25%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range4.46 - 7.00 Perf YTD-20.00%
Dividend0.60 P/FCF- EPS past 5Y- ROI- 52W High-28.57% Beta-
Dividend %12.00% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low12.11% ATR0.30
Employees14 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)47.87 Volatility1.40% 2.85%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.04 Prev Close5.00
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume1.13K Price5.00
Recom- SMA20-1.25% SMA50-6.18% SMA200-17.94% Volume0 Change0.00%
May-14-19 04:05PM  Cyclacel Pharmaceuticals Reports First Quarter 2019 Financial Results GlobeNewswire
May-08-19 07:00AM  Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results GlobeNewswire
Apr-01-19 07:00AM  Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019 GlobeNewswire -5.11%
Mar-27-19 04:05PM  Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Mar-26-19 12:46PM  Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action Benzinga -5.80%
Mar-25-19 07:00AM  Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor GlobeNewswire
Mar-20-19 07:00AM  Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire +8.22%
Mar-13-19 07:00AM  Cyclacel to Participate in 31st Annual ROTH Conference March 18-19 GlobeNewswire
Mar-05-19 07:00AM  Cyclacel Announces Abstracts Selected for Presentation at the American Association for Cancer Research Annual Meeting 2019 GlobeNewswire
Feb-05-19 07:00AM  Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference GlobeNewswire
Jan-07-19 07:00AM  Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019 GlobeNewswire -9.77%
Dec-27-18 07:00AM  Cyclacel Pharmaceuticals to Present at Biotech Showcase 2019 in San Francisco GlobeNewswire
Nov-12-18 04:05PM  Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results GlobeNewswire +11.13%
Nov-06-18 07:00AM  Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results GlobeNewswire
Oct-23-18 07:00AM  Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference GlobeNewswire
Oct-04-18 07:00AM  Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies GlobeNewswire
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.